Topics:

AVEO Initiates Phase I Trial of AV-412 in Solid Tumors

AVEO Initiates Phase I Trial of AV-412 in Solid Tumors

CAMBRIDGE, Massachusetts—AVEO Pharmaceuticals, Inc., has begun enrolling patients with advanced solid tumors in a phase I clinical study of AV-412, a next-generation oral tyrosine kinase inhibitor of EGFR and HER2. In preclinical studies, AV-412 has shown activity in various tumor models, has a toxicity profile similar to other molecules in its class, and has shown preclinical activity against tumor cells that are resistant to first-generation tyrosine kinase inhibitors, the company said in a press release.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.